Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Insulin LAI287 offers potential for once-weekly dosing
LAI287 pharmacodynamic profile is compatible
with once-weekly dosing
Glucose Infusion Rate
(mg/kg/min)
5
4
3
2
1-
Insulin glargine
0
1 2
3
4
5
10
Time (days)
Note: Pharmacokinetic simulation
changing
diabetes®
LAI287
•
16
7
Slide 77
•
Key results of phase 1 trial
The trial evaluated short term efficacy and safety during
five weeks of treatment
LAI287 showed dose-dependent exposure and a variability
comparable to that of insulin degludec
Terminal half-life of 185 hours supporting a once-weekly
dosing regimen
LAI287 generally appeared safe and well tolerated, with
most frequent adverse events being hypoglycaemia
The side effects observed in the phase 1 trial will be
further investigated
novo nordiskView entire presentation